Abstract: The application provides a method of detecting an analyte in a sample. The method comprises disposing a binding agent in an electrochemical compartment. The binding agent is configured to bind to an interfering species. The method further comprises disposing a solution comprising a sample in the electrochemical compartment. The sample comprises an analyte and the interfering species. The method then comprises applying a voltage across first and second spaced apart electrodes disposed in the solution, and thereby causing a current to flow through the solution between the electrodes. Finally, the method comprises measuring the current and/or voltage and thereby detecting the analyte.

Abstract: In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a human subject suffering from graft-versus-host disease and/or diffuse alveolar hemorrhage and/or veno-occlusive disease associated with a hematopoietic stem cell transplant. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation.

Abstract: In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.

Abstract: This invention relates to methods of detecting Borrelia burgdorferi sensu lato or for detecting Borrelia associated with Relapsing Fever (RF), kits for carrying out such methods, and methods of treating Borrelia burgdorferi sensu lato or RF infections in a subject. Uses of phage specific for Borrelia are also provided.

Abstract: The disclosure provides compounds of formula (I). The compounds may be used to degrade the Histone Deacetylase (HDAC) family of enzymes, particularly HDAC1, 2 and 3 that exist in corepressor complexes. Accordingly, the compounds may be used to treat cancer. The invention extends to pharmaceutical compositions comprising these compounds, and the use of these compounds in therapy.

Abstract: The invention relates to methods of detecting mutations associated with the Ras homologue gene family member (RHOA) gene, and diagnosing conditions associated with these mutations, using Competitive allele-specific TaqMan polymerase chain reaction (cast-PCR). The invention also extends to the products used to detect mutations, and their use in diagnosis.

Abstract: In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject suffering from, or at risk for developing a thrombotic microangiopathy (TMA). The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact.

Abstract: A method of assessing the effect of viewing varying colours of light on a subject's perception of tinnitus, comprising the steps of: presenting a display in at least part of the subject's field of view; illuminating the display with coloured light in the visible spectrum using one or more variable sources, varying measurable values of the coloured light illuminating the display; and recording the measurable values of the coloured light illuminating the display at which the subject indicates a change in their perception of tinnitus.

Abstract: A medical device for assisting the break-up, disruption or disintegration of calcified or other hardened material within vessels of the human or animal body which material otherwise prevents or inhibits stenting procedures or passage of guidewires, catheters and other devices through the vessels. The device includes a catheter having a lumen extending between a distal end and a proximal end of the catheter and a displaceable element at the distal end of the catheter configured for axial and/or radial displacement relative to the catheter when driven by pressure fluctuations within the lumen. A pressure pump is coupled to a proximal end of the catheter and is configured for application of a baseline pressure to the catheter lumen. A pressure modulation source is also coupled to the proximal end of the catheter, configured to modulate the baseline pressure in the catheter lumen with one or more pressure impulses, and preferably with a series of pressure pulses.

Abstract: The invention relates to senescent cell biomarkers and the uses thereof. The invention also extends to methods and kits for detecting senescence, and drug conjugates and pharmaceutical compositions for killing senescent cells.

Abstract: In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a human subject suffering from graft-versus-host disease and/or diffuse alveolar hemorrhage and/or veno-occlusive disease associated with a hematopoietic stem cell transplant. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation.

Abstract: A method for assessing the electrical function of a heart that includes: (1) for each of a plurality of leads of an ECG, determining a value derived from the output of that lead and which corresponds to an action potential duration; (2) for each of the plurality of leads of the ECG, determining a value derived from the output of that lead and which corresponds to a diastolic interval; (3) for each of the plurality of leads of the ECG, determining a relationship between the determined values for action potential duration and for diastolic interval; and (4) assessing the differences between the determined relationships for each of the plurality of leads. The invention further relates to apparatus and a computer program that may be used in the method.

Abstract: The invention relates to aortopathy, and in particular, to compositions and methods for the diagnosis and treatment of aortopathy.

Abstract: In one aspect, the present invention provides methods for preventing, treating, reverting and/or delaying angiogenesis in a mammalian subject suffering from, or at risk for developing, an angiogenesis-dependent disease or condition, comprising administering to the subject an amount of a MASP-2 inhibitory agent effective to inhibit angiogenesis. In some embodiments of these aspects of the invention, the MASP-2 inhibitory agent is a MASP-2 antibody or fragment thereof.

Abstract: There is provided the use of at least one ionic liquid as a soldering/brazing flux. There is also provided a method of soldering a metal comprising applying a solder/braze comprising a flux to a surface of the metal and heating said metal to a desired soldering/brazing temperature, wherein the soldering/brazing flux comprises one or more ionic liquids.

Abstract: The invention provides a two-step approach to providing a BCI system. In a first step the invention provides a low-power implantable platform for amplifying and filtering the extracellular recording, performing analogue to digital conversion (ADC) and detecting action potentials in real-time, which is connected to a remote device capable of performing the processor-intensive tasks of feature extraction and spike classification, thus generating a plurality of predetermined templates for each neuron to be used in a second processing step. In the second step the low-power implantable platform amplifies and filters the extracellular recording, performs ADC and detects action potentials, which can be matched on-chip to the predetermined templates generated by the external receiver in the first step.

Abstract: In one aspect, the invention provides methods for treating, inhibiting, alleviating or preventing fibrosis in a mammalian subject suffering, or at risk of developing a disease or disorder caused or exacerbated by fibrosis and/or inflammation. In one embodiment, the invention provides methods of treating a subject suffering from renal fibrosis. In one embodiment, the invention provides methods of reducing proteinuria in a subject suffering from a renal disease or condition associated with proteinuria. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation.

Abstract: A method of assessing the effect of viewing varying colours of light on a subject's perception of tinnitus, comprising the steps of: presenting a display in at least part of the subject's Held of view; illuminating the display with coloured light in the visible spectrum using one or more variable sources, varying measurable values of the coloured light illuminating the display; and recording the measurable values of the coloured light illuminating the display at which the subject indicates a change in their perception of tinnitus.

Abstract: There is provided an electrolyte for the electrodeposition of chromium comprising: (A) water; (B) at least one chromium salt; and (C) at least one complexing agent, wherein the molar ratio of components B:C is in the range of 1:1 to 1:50. There is also provided a method for electrodepositing chromium metal onto a conductive substrate.

Abstract: Genetically modified mammals are described which lack the mannan binding lectin associated serine protease MASP-2, together with methods and constructs for their production. Such mammals are useful as models for disorders of the complement system, and in the identification of treatments for such disorders. Also described are mammals which lack the associated protein MAp19; such mammals may also lack MASP-2.